[Clinical features and response to systemic treatment of primary and secondary episcleritis and scleritis resistant to local treatment]

Rev Med Chil. 2000 Nov;128(11):1205-14.
[Article in Spanish]

Abstract

Background: Scleritis and episcleritis may extend to adjacent ocular tissues with blinding consequences and may be associated with potentially lethal systemic disorders.

Aim: To evaluate the ocular complications and systemic disease associations of the different types of scleritis and episcleritis.

Patients and methods: Forty six patients with refractory scleritis and episcleritis were studied and treated during the period 1991 to 1998.

Results: Necrotizing type was the most common and severe category in the scleritis group of patients. A decrease in vision occurred in 58.3% of patients with scleritis v/s a 23.5% of patients with epiescleritis (p < 0.05). Uveitis was present in 35.4% of patients with scleritis and scleromalacia was present in 33.3% (p < 0.05). A specific disease association was uncovered in 51% of scleritis and in 38% of episcleritis patients. Rheumatoid arthritis, primary systemic vasculitic disease and Sjögren syndrome with vasculitis were the most common associated systemic diseases. Three patients with scleritis had tuberculosis.

Conclusions: Scleritis is more severe than episcleritis, and necrotizing scleritis is the most severe type of scleritis. Classification of scleritis and episcleritis provides valuable prognostic information. A meticulous approach for the detection of a specific associated disease must be undertaken. Scleritis associated with vasculitis has a worse ocular prognosis than other non infectious diseases. Cyclophosphamide is the most effective immunosuppressive treatment to control severe ocular involvement.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Radiography
  • Recurrence
  • Scleritis / complications
  • Scleritis / diagnostic imaging
  • Scleritis / drug therapy*
  • Treatment Outcome